Definium Therapeutics, Inc. 4

CEO Robert Barrow received an award of 375,000 performance-based common shares of Definium Therapeutics, Inc. on August 12, 2026.

On August 12, 2026, Robert Barrow, Chief Executive Officer of Definium Therapeutics, Inc., received an award of 375,000 common shares at a reported price of $0.00 per share, representing the second tranche of performance share units originally granted on March 12, 2025. These shares remain subject to vesting based on his continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement. Following this award, Barrow’s direct beneficial ownership increased to 1,473,246 common shares. With no current market price data provided, the dollar value of both the grant and his post-transaction holdings cannot be precisely estimated from the filing excerpt.

Filing Facts

CIK

1813814

Ticker

DFTX

Form

4

Source Type

fda

Accession

0001193125-26-345839

Alert Tier

5